Sermorelin vs Somatropin (recombinant human growth hormone)
Somatropin replaces GH directly in licensed indications; sermorelin stimulates endogenous release and has historical GHRH evidence. Neither comparison supports healthy-person anti-ageing claims.
| Attribute | Sermorelin | Somatropin (recombinant human growth hormone) |
|---|---|---|
| Human evidence | Native GHRH(1-29)/sermorelin has genuine human endocrine and diagnostic evidence. In a tiny 6-week study of older men, nightly GHRH increased nocturnal GH but did not significantly improve IGF-I or DEXA body composition. | Somatropin has extensive approved replacement evidence in diagnosed growth-hormone deficiency. In healthy older adults, systematic review evidence found modest body-composition changes with increased adverse effects and no basis for a broad anti-ageing claim. |
| Research focus | Growth-hormone diagnostic/deficiency research | Growth hormone deficiency and other licensed indications |
| Regulatory status | Historical FDA marketing approval existed for Geref (sermorelin acetate); this does not confer approval on generic research-market sermorelin. | Multiple licensed somatropin products exist. An unverified product labelled as HGH or somatropin is not automatically an approved or quality-assured medicine. |
| Route / formulation | Current authorization and product quality must be checked by jurisdiction/product. | Quality, sterility, dose accuracy and authenticity of research-market HGH must be independently verified. |
Why these are compared
These compounds appear in the gh-axis therapy / enhancement claims evidence landscape, but they are not interchangeable. Sermorelin is ghrh(1-29) peptide analogue studied in growth-hormone diagnostic/deficiency research; Somatropin (recombinant human growth hormone) is 191-amino-acid recombinant protein hormone studied in growth hormone deficiency and other licensed indications. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Sermorelin: Established human endocrine pharmacology; historical clinical use; lifestyle benefits unproven.
Somatropin (recombinant human growth hormone): Approved medicine for defined indications; healthy-person anti-ageing use has limited benefit-risk evidence.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
Different mechanisms and approved contexts. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.